Changes in depression symptom profile with gender-affirming hormone use in transgender persons 83 The cluster scores based on the symptom clusters found in the EFA analysis showed no significant changes after 3 or 12 months of GAHT in the total cohort (i.e. TM and TF groups together). In the TM group, the subscales for mood, anxiety, and somatic symptoms did not show significant changes after 3 or 12 months of GAHT. However, the TM group showed a significant decrease in lethargy symptoms (-16.3%, 95% CI: -28.5% to -2.0%, p=0.03) after 3 months of GAHT, but no significant change after 12 months of GAHT compared to baseline. In the TF group, the total subscales for anxiety, lethargy, and somatic symptoms did not significantly change after 3 months or 12 months of GAHT. The TF group showed a significant increase in mood symptoms after 12 months of GAHT (+24.3%, 95% CI: 2.6%; 50.6%, p=0.03) compared to baseline. It must be noted that although the subscores in lethargy and mood in the TM and TF groups show changes after starting GAHT use, the medians of the subscores are and remain below 3 points during GAHT use. Absolute scores per time point and full results of all longitudinal models are displayed in Table 3.2, and the estimated changes are displayed in Figure 3.4. Sensitivity analyses Sensitivity analyses assessing the effects of only complete GAHT in the TF group, excluding users of incomplete GAHT (i.e. use of estradiol or antiandrogens, but not both), show similar estimates and effect sizes compared to analyses in the full sample, as reported in Supplementary Table S3.1. Sensitivity analyses adjusted for age, cohort, cycle regulation use, testosterone form (i.e. transdermal or injections) and estrogen form (i.e. transdermal or oral) also show similar estimates, as reported in Supplementary Table S3.2. Higher age was significantly associated with higher IDS-SR scores, but the addition of age did not change estimated outcomes for the total IDS-SR.
RkJQdWJsaXNoZXIy MTk4NDMw